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Pulmonary arterial hypertension (PAH) is a vascular remodeling disease of the lungs resulting in heart failure
and premature death. Although, until recently, it was thought that PAH pathology is restricted to pulmonary
arteries, several extrapulmonary organs are also affected. The realization that these tissues share a common
metabolic abnormality (i.e., suppression of mitochondrial glucose oxidation and increased glycolysis) is
important for our understanding of PAH, if not a paradigm shift. Here, we discuss an emerging metabolic
theory, which proposes that PAH should be viewed as a syndrome involving many organs sharing a mito-
chondrial abnormality and explains many PAH features and provides novel biomarkers and therapeutic
targets.Introduction
Pulmonary arterial hypertension (PAH) is a vascular remodeling
disease of the lungs that causes right ventricular failure and
death within a few years from diagnosis (McLaughlin et al.,
2009). The definition of PAH and the spectrum of associated
conditions has been changing in part because of improved ability
to diagnose it earlier and more accurately. Although its exact
incidence and prevalence remain unknown in the modern era,
PAH appears to be more frequent than previously thought. How-
ever, because of its high mortality, the relatively young age of the
affected patients, and the very high cost of available therapies,
this disease has a significant impact on society. For example,
the mortality of severe PAH is similar to that of metastatic breast
cancer, whereas the currently estimated cost of the treatment of
advanced PAH per patient exceeds $200,000 a year (Chen et al.,
2009). Current therapies for PAH remain poor in terms of their
ability to reverse the disease or significantly prolong survival
(Archer and Michelakis, 2006; Macchia et al., 2007; McLaughlin
et al., 2009) despite major advances in the field over the recent
years (Archer et al., 2010b; Rabinovitch, 2012). A major limitation
continues to be selectivity, given that all therapies currently used
in PAH can affect the systemic vessels, which generally appear
intact in PAH. In fact, all of the therapies currently used for
PAH treatment, were originally developed as systemic vasodila-
tors (Archer and Michelakis, 2006) and were tried in PAH only
upon their failure in systemic vascular disease or approaching
patent expirations. Over the past 10 years, there has been a
paradigm shift in the treatment of this disease. Whereas, early
on, it was thought that vasoconstriction plays a critical role in
directing therapeutic development on vasodilators, it is now
known that the basis of the disease is a proliferative vascular re-
modeling, not vasoconstriction. In addition, myriads ofmolecular
abnormalities in pulmonary vascular cells and associated condi-
tions or triggers of the disease have been identified and recently
reviewed (Archer et al., 2010b; McLaughlin et al., 2009; Rabino-
vitch, 2012). Although they all appear to promote proliferation
and suppress apoptosis in pulmonary vascular cells, whether
they are related to each other remains unknown. The develop-
ment of comprehensive theories for PAH may improve our558 Cell Metabolism 19, April 1, 2014 ª2014 Elsevier Inc.understanding of the disease and facilitate the development
and translation of effective therapies and biomarkers.
A foundation of PAH pathology, since its original description
by Dresdale et al. (1951), has been the fact that the abnormalities
are restricted within the pulmonary vascular bed, a circulation
with different embryology and physiology in comparison to the
systemic circulation. Yet, there is growing evidence that a num-
ber of extrapulmonary tissues and cell types (right ventricular
cardiomyocytes, immune cells, bone-marrow-derived precursor
cells, and skeletal muscle) are also abnormal, suggesting that
PAH could perhaps be seen as a syndrome rather than a disease
of the pulmonary arteries. There appear to be molecular and
biochemical similarities in the pathology ofmany of these extrap-
ulmonary tissues, suggesting the need for a new comprehensive
view in this disease. Here, we discuss an emerging theory, the
metabolic theory of PAH, that aims to facilitate our understand-
ing of the disease by proposing that several diverse molecular
signatures of the disease are related and are a part or a conse-
quence of ametabolic remodeling in the vascular cells of the pul-
monary circulation as well as extrapulmonary tissues. In addition
to proposing that PAH should perhaps be approached as a syn-
drome with multiorgan involvement, the metabolic theory puts
the mitochondria in the center of the pathogenesis of this com-
plex and still mysterious disease. The theory also aims to facili-
tate the diagnosis and treatment of PAH by revealing several
keymetabolic targets that are directly involved in PAHpathogen-
esis and can form the basis of biomarker and drug discovery
programs. Therapies or biomarkers emerging from a compre-
hensive theory may be better in terms of comprehensively
addressing several fundamental aspects of the disease, as
opposed to those arising from a single gene/molecular pathway.
The Clinical Syndrome of PAH
PAH is clinically defined by an increase in the mean pulmonary
artery pressure of more than 25 mmHg at rest and normal left
ventricular filling pressures in the absence of diseases that could
‘‘mimic’’ this hemodynamic profile (such as chronic obstructive
pulmonary disease, interstitial lung disease, or thromboembolic
lung disease) (McLaughlin et al., 2009). The pathology of PAH is
Cell Metabolism
Perspectivecharacterized by a remodeling of the small- to medium-sized
pulmonary arteries, which decreases their luminal cross-
sectional area. The resulting increase in the peripheral vascular
resistance (PVR) increases the afterload of the right ventricle
(RV) and results in a short-lived compensatory RV hypertrophy,
which progresses to a decompensation phase, a decrease in
the cardiac output, heart failure, and death (Haddad et al.,
2008a). The normal pulmonary circulation is characterized by
much higher capacitance than the systemic circulation, meaning
that significant vascular remodeling can take place before the
pulmonary artery pressure increases and the cardiac output
decreases. Thus, patients present late in the course of the dis-
ease, and even then their symptoms are nonspecific, including
dyspnea on exertion and shortness of breath, syncopewith exer-
tion, weakness, and fluid retention, all a result of the decreased
cardiac output. The morbidity of PAH relates to a combination of
the progressive pulmonary artery vascular remodeling and the
relatively short-lived RV compensation, at least in comparison
to the left ventricle (LV) in systemic hypertension (McLaughlin
et al., 2009).
In 2008, the Dana Point classification of PAH expanded and
categorized PAH into five distinct groups: (1) idiopathic PAH,
(2) heritable PAH (HPAH), (3) drug- and toxin-induced PAH, (4)
associated PAH (APAH), and (5) persistent pulmonary hyperten-
sion of the newborn (Simonneau et al., 2009). The APAH group is
large, and the PAH in these patients is associated with autoim-
mune collagen diseases such as scleroderma, congenital heart
disease, or HIV infection, among others.
The exact current survival rates of PAH are unknown. How-
ever, the 3- and 5-year survival rates from a prospective multi-
center National Institutes of Health (NIH) registry in the 1980s
suggested they were 48% and 34%, respectively (D’Alonzo
et al., 1991). More recent data suggest that the current 5-year
survival is a little higher (50%) (McLaughlin et al., 2009), but this
is mostly because the disease can now be diagnosed much
earlier, in comparison to the 1980s, when Doppler Echocardiog-
raphy (a major screening tool) was not available. Subpopulations
of APAH patients not specifically studied in the NIH registry,
such as scleroderma or HIV infection, have 5-year survival rates
less than 40% or 20%, respectively (McLaughlin et al., 2009).
The exact incidence and prevalence of the disease also remain
unknown. The prevalence of PAH had been estimated to be
0.005% in the past, but this is most likely an underestimation
in the modern era (McLaughlin et al., 2009; Peacock et al.,
2007). Currently, increased awareness and wide availability of
screening tests (like Doppler Echocardiography) result in earlier
and more efficient diagnosis of the disease. Within certain
high-risk groups, the prevalence is higher. For example, within
patients with HIV infection the prevalence is 0.5% (Sitbon
et al., 2008) and within patients with scleroderma is as high as
12% (Hachulla et al., 2005).
Current therapies for PAH patients are categorized into three
classes of drugs that were originally developed as vasodilators:
(1) prostacyclin synthetics and analogs, (2) endothelin receptor
antagonists (ERAs), and (3) phosphodiesterase type 5 inhibitors
(PDE5i). Current practice suggests that the first line use of an
ERA or PDE5i as a monotherapy in patients at earlier stages of
the disease (World Health Organization [WHO] functional class
II or III), whereas the addition of a parenteral prostacyclin syn-thetic/analog is reserved for patients at more advanced stages
of the disease (WHO functional class IV) (McLaughlin et al.,
2009). None of these drugs have been shown to effectively
reverse the disease or significantly improve long-term survival
and eventually lung or lung and heart transplantation may be
the only life-saving option for the many patients that continue
to progress. These therapies are not selective to the pulmonary
circulation, and, whereas some were subsequently shown to
also limit the proliferative potential of vascular cells, they do
not directly address the pathology of the disease, which includes
both a strong hyperproliferative and apoptosis-resistant remod-
eling of the pulmonary arteries.
The Pathology of PAH
It is now becoming increasingly recognized that the pathology of
PAH is not restricted to the lung but also includes abnormalities
to the RV, spleen (activation of immune cells), bone marrow
(endothelial precursor cells), and skeletal muscle (insulin resis-
tance) (Figure 1). Excellent and systematic description of the
lung pathology of human PAH has recently been published
(Stacher et al., 2012). Here, we focus on the approach of the
PAH pathology as a syndrome that also involves many extrapul-
monary tissues. After a summary of the pathology of these tis-
sues, we describe the evidence that suggests that a common
metabolic and mitochondria-based remodeling may underlie
the pathology of most of these tissues.
The Pulmonary Arteries
The pathology of the pulmonary arteries in the lungs of PAH
patients is complex and includes intima and media thickening
of the pulmonary arteries. In addition, many lungs also have
plexogenic lesions, which resemble ‘‘misguided angiogenesis’’
with anarchous proliferation of endothelial, smooth muscle cells,
and fibroblasts in and around occluded pulmonary arteries
(Stacher et al., 2012). Infiltration of the perivascular space or
vascular wall with immune and inflammatory cells is more prev-
alent than previously thought (Stacher et al., 2012). These
changes cause a vascular remodeling that eventually leads to
a narrowing or obliteration of the vascular lumen.
Many of the vascular cells involved in these lesions maintain a
proliferative and antiapoptotic phenotype even when isolated
and cultured in vitro. Regardless of the animal model they
come from, both animal and human PAH PA smooth muscles
cells (PASMCs) express many cancer markers, have acti-
vated oncogenes, and master transcription factors including
hypoxia-inducible factor 1a (HIF1a; even under normoxia) or
nuclear factor of activated T cells (NFAT) and have increased
intracellular calcium levels, in part because of a downregulation
of plasmalemal voltage-gated potassium channels (Kv) (Drom-
paris and Michelakis, 2013; Dromparis et al., 2010). BMPRII
germline loss-of-function mutations have been described in
many HPAH cases but in the minority of sporadic PAH cases
(Newman et al., 2001), although, in such cases, abnormalities
in the SMAD signaling, downstream of BMPRII have also been
described (Morrell et al., 2009; Sobolewski et al., 2008). Many
more molecular abnormalities have been described, summa-
rized recently in excellent reviews (Archer et al., 2010b;
McLaughlin et al., 2009; Rabinovitch, 2012).
The natural history of the vascular remodeling in human PAH
remains unknown (Stacher et al., 2012) in part because serialCell Metabolism 19, April 1, 2014 ª2014 Elsevier Inc. 559
Figure 1. PAH Is a Multiorgan Disease
In addition to the proliferative remodeling in the
small pulmonary arteries in the lung, several
organs are involved in PAH, suggesting that
this disease can be approached as a syndrome
with multiorgan involvement. The right ventricle
(RV) is remodeled; following a short-lived com-
pensatory hypertrophy, the RV dilates and fails,
causing a decrease in cardiac output, which
explains most PAH symptoms and the early
morbidity from heart failure. A plethora of
immune cells are activated, and activated T cells
play a critical role. The serum of PAH patients
is characterized by increased levels of several
inflammatory cytokines, and the immune cells
recruited in the lungs contribute (in a paracrine
manner) to the proliferative vascular remodeling.
Several bone-marrow-derived precursor cells
(and, particularly, precursor endothelial cells) also
contribute to the proliferative remodeling as
they are recruited to the diseased pulmonary
circulation, perhaps in an attempt to regenerate
or repair the remodeled pulmonary circulation.
PAH patients also have several features of an
insulin resistance and/or metabolic syndrome
with increased glucose, insulin, and lipids. As in
the classic metabolic syndrome, where skeletal
muscle is a major site of insulin resistance, the
characteristic lipid deposition is also seen in PAH
skeletal muscle.
With the exception of precursor bone marrow
cells, where metabolism has not yet been studied,
all the other tissues show evidence of direct
mitochondrial dysfunction, resulting in sup-
pressed oxidative phosphorylation and glucose
oxidation (GO) and a secondary upregulation of
glycolysis (Gly).
The photomicrographs show (1) a remodeled
small pulmonary artery from a patient with PAH
exhibiting medial hypertrophy (smooth muscle
actin staining pulmonary artery smooth muscle
cells; presented with permission from Michelakis
et al., 2008), (2) a dilated RV from an autopsy
specimen from a PAH patient, and (3) skeletal muscle from a mouse with PAH showing increased lipid deposition, a picture that exactly mimics skeletal
muscle from patients with insulin resistance (Oil Red O staining is shown; taken with permission from West et al., 2013).
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of the many limitations of the available animal models and their
failure to completely model the human disease (Stenmark
et al., 2009). However, although it has been hypothesized that
the first abnormality in the pulmonary circulation includes an
injury in PA endothelial cells (PAECs), leading to their apoptosis
and the triggering of a vascular repair program that ‘‘goes
wrong,’’ it appears that, when the disease is fully developed,
PAECs, PASMCs, and fibroblasts all show increased prolifera-
tion, migration, and resistance to apoptosis (Dromparis and Mi-
chelakis, 2013; Dromparis et al., 2010; Tuder et al., 1994; Voelkel
et al., 1998).
The Right Ventricle
The increase in afterload results in RV hypertrophy (RVH), which,
much like the LV hypertrophy (LVH) that develops in systemic
hypertension, is an adaptive mechanism designed to maintain
cardiac output. However, in sharp contrast with LVH, the adap-
tive and/or compensated RVH phase is much shorter, leading to
a rapid RV functional deterioration, RV dilatation, and premature
death from heart failure (Voelkel et al., 2006). It is now known that
the most important predictive factor for PAH is not the degree of
vascular remodeling or the increase in pulmonary artery pressure
but the RV function itself (Haddad et al., 2008a). What drives the560 Cell Metabolism 19, April 1, 2014 ª2014 Elsevier Inc.transition from compensated to decompensated RV function
remains unknown. Intriguingly, recent data show that some
patients treated with approved PAH therapies go on and deteri-
orate with worsened RV function, despite a positive hemody-
namic response to therapy (i.e., despite a decrease in PA pres-
sure) (van de Veerdonk et al., 2011). This suggests that there
may be mechanisms intrinsic to the RV that are independent of
the degree of PA vascular remodeling, which determine the pro-
gression of RV function toward failure. The many differences
between the LV and RV, including their different embryology
(Haddad et al., 2008b), support the existence of mechanisms
of decompensation intrinsic to the RV, perhaps independent of
the sustained pressure overload.
The Spleen and the Immune System
Inflammation is an increasingly recognized component in all
groups of PAH and increased cytokines produced by activated
immune cells, such as tumor necrosis factor a (TNFa) and inter-
leukins, are found in the serum of PAH patients, and their levels
correlate positively with the severity of the disease (Dorfmu¨ller
et al., 2003; Hassoun et al., 2009; Kherbeck et al., 2013; Price
et al., 2012). Activation of many circulating immune cells within
the spleen (but also of cells native to the lungs) has been docu-
mented in PAH, and a large number of these (macrophages,
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play a central role) are recruited to or activated within the pulmo-
nary circulation and found either within the vessel wall or in the
immediate perivascular areas (Savai et al., 2012; Stacher et al.,
2012). These cells have been shown to regulate the function
and differentiation status of the pulmonary artery cells in a para-
crinemanner. The emerging inflammatory theory of PAH is also a
promising comprehensive theory in PAH, which, like the meta-
bolic theory, may explain many diverse features of the disease
(Kherbeck et al., 2013; Price et al., 2012).
The Bone Marrow
Bone-marrow-derived cells play an important role in PAH
vascular remodeling. Although this is not yet proven in human
PAH, the recruitment of endothelial, smoothmuscle, or fibroblast
precursor cells from the bone marrow could represent an
attempt for tissue regeneration and/or repair in response to injury
and the apoptosis of the normal PAEC at the earliest stages of
the disease (Yeager et al., 2011). Furthermore, the inflammatory
environment in the remodeled PAH vessels and the increased
levels of inflammatory cytokines could attract and recruit bone
marrow cells. In both human tissues and animal models, hypoxia
(an environmental trigger of pulmonary hypertension) triggers the
mobilization of c-Kit+ bone-marrow-derived cells that are re-
cruited to the adventitia and vasa vasora of the remodeled pul-
monary arteries, where they have the potential to differentiate
into both endothelial and smooth muscle cells, particularly under
inflammatory conditions (Yeager et al., 2011).
The Skeletal Muscle
It is now becoming increasingly recognized that PAH patients
may have features of the metabolic syndrome and insulin resis-
tance (Zamanian et al., 2009), suggesting that the skeletal mus-
cle (a major target tissue of insulin) in PAH patients may have a
yet unexplored metabolic abnormality. Nonobese or diabetic
PAH patients have signs of insulin resistance with increases in
glucose and insulin levels as well as lipids, a clinical picture
that resembles the metabolic syndrome (Heresi et al., 2010;
Pugh et al., 2011).
There are two important questions: (1) with the many signaling
abnormalities described, where should the therapeutic efforts
focus, and (2) given that there appears to be involvement of
many organs and tissues, why are the pulmonary vessels
affected, whereas the systemic vessels appear to be spared?
We believe that the metabolic theory of PAH may provide clues
and answers to these important questions. As we discuss below,
mitochondria signaling appears to integrate many diverse trig-
gers of PAH, suggesting that reversing themitochondrial remod-
eling in PAH vessels may reverse the disease regardless of the
primary signal. Also, the differences of the mitochondria be-
tween the pulmonary and systemic circulations may explain
why the pulmonary vessels are so much more ‘‘sensitive’’ to
mitochondrial remodeling.
Mitochondria and the Pulmonary Circulation
Mitochondria Are the Basis of Hypoxic Pulmonary
Vasoconstriction
The most critical difference between the pulmonary circulation
and the systemic circulation is their response to hypoxia. Given
that lungs are the primary ‘‘distributors’’ of oxygen and the
peripheral systemic organs are ‘‘consumers’’ of oxygen, it isnot surprising that the pulmonary arteries constrict, whereas
the systemic arteries dilate, in response to hypoxia. Hypoxic pul-
monary vasoconstriction (HPV) is present in all mammals and
contributes to the maintenance of ventilation-perfusion match,
given that the constriction of a pulmonary artery in a hypoxic
area redirects the blood to better-oxygenated areas of the lung
(Weir et al., 2005). The physiology of HPV has been studied for
decades, and PASMC mitochondria, well-recognized O2 sen-
sors in many O2-sensitive tissues, have emerged as its basis
(Weir et al., 2005). As O2 sensors, mitochondria can alter the pro-
duction of mitochondria-derived reactive O2 species (mROS),
which can diffuse to the cytoplasm and the plasma membrane
and regulate redox-sensitive targets that can induce acute
PASMC contraction, such as the membrane Kv channels or
redox-sensitive components of the HIF1a-signaling pathway.
Inhibitors of the mitochondrial electron transport chain (ETC)
complexes I and III, the main producers of mROS, completely
mimic the opposing responses of PASMCs versus systemic
artery vascular SMCs to hypoxia (Michelakis et al., 2002a). Dif-
ferences in PASMCmitochondria in comparison tomitochondria
from systemic vascular SMCs (e.g., decreased expression and
function of ETC complexes I–III and increased expression of
manganese superoxide dismutase, which could explain the dif-
ferences in the mROS production at baseline and the opposite
response to hypoxia) provide an attractive explanation for the re-
striction of HPV within the pulmonary circulation (Michelakis
et al., 2002a). The resistance pulmonary arteries are normally
exposed to much higher levels of oxygen in comparison to sys-
temic arteries (>120 versus <50 mmHg, respectively), and this
much higher level of oxidative stress suggests pulmonary-artery-
specific mechanisms of defense to oxidative stress and perhaps
more ‘‘adapted’’ mitochondria.
Could such differences also provide clues on why the pathol-
ogy of PAH is restricted to the pulmonary vessels, sparing sys-
temic vessels? In fact, mitochondria can play important roles in
the resistance to apoptosis, the signaling abnormalities, and
the proliferative and proinflammatory potential described in
PAH vessels.
Mitochondria Can RegulateMultiple Aspects of Vascular
Function
Mitochondria integrate many environmental and molecular sig-
nals (Dromparis and Michelakis, 2013). For example, many
known oncogenes or tumor suppressor proteins, such as p53
or cMyc, directly regulate mitochondrial function (Ward and
Thompson, 2012), and, similarly, environmental factors such as
hypoxia and fundamental cellular responses such as endo-
plasmic reticulum (ER) stress or inflammation also directly regu-
late mitochondrial function (Dromparis and Michelakis, 2013). In
turn, mitochondria respond in a variety of ways (beyond their
traditional view as producers of ATP and heat) with the produc-
tion of diffusible mediators and redox signals that can regulate
multiple critical components of cellular function (Figure 2) (Drom-
paris et al., 2010). As discussed below, mROS or diffusible
metabolites such as a ketoglutarate (aKG) can regulate tran-
scription factors such as NFAT and HIF1a, both of which play
critical roles in the vascular remodeling characterizing PAH.
Mitochondria products such as aKG and citrate are critical for
epigenetic mechanisms, including histonemethylation and acet-
ylation, respectively, which have been shown to play a role inCell Metabolism 19, April 1, 2014 ª2014 Elsevier Inc. 561
Figure 2. Mitochondria Integrate Diverse Stimuli and Respond in a
Manner that Affects Many Cellular Functions
Mitochondrial function can be regulated by fuel supply along with intracellular
and extracellular inputs. Intracellular inputs include local signals, such as
endoplasmic reticulum (ER)-derived calcium, which is important for the
regulation of many mitochondrial enzymes, or nuclear signals, which include
chaperone proteins and nucleus-encoded mitochondrial proteins, which can
affect global mitochondrial function (such as pyruvate dehydrogenase) or
factors that regulate mitochondrial networks (mitogenesis, fission, and fusion).
Extracellular signals include circulating hormones (such as the thyroid hor-
mone that can regulate mitochondrial biogenesis), cytokines (such as TNFa,
which can directly inhibit PDH), or paracrine signals such as nitric oxide (which
can directly regulate the function of mitochondrial ETCs) or vasoconstrictors
(which can regulate the levels of ER calcium, and thus calcium supply, into
the mitochondria). The mitochondria respond to these inputs by generating
ATP, heat, or signaling molecules, which are important for local, intracellular,
or systemic signaling pathways. The mitochondria can activate the in-
flammasome, regulate transcription factors, activate the apoptosome, regu-
late epigenetic mechanisms, or activate ion channels, regulating vascular tone
resistance to apoptosis and proliferation. In addition, it has recently been
proposed that, when distressed, the mitochondria can release mitokines,
which can ‘‘condition’’ remote organs. Thus, the mitochondria are well suited
to play important roles in complex multifactorial diseases such as PAH.
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regarding fuel supply (oxygen, glucose, and lipids) and optimize
cellular growth to the availability of fuel by regulating cell death.
Mitochondria are major regulators of apoptosis, and multiple
lines of evidence suggest that mitochondria-dependent apo-
ptosis is suppressed in PAH (Dromparis et al., 2010). Lastly,
although inflammatory cytokines can suppress mitochondria
function (for example, TNFa inhibits pyruvate dehydrogenase
[PDH, the gatekeeping enzyme for glucose oxidation in the mito-
chondria], causing a suppression of glucose oxidation), mito-
chondria themselves can activate the inflammasome NLPR3
(Kepp et al., 2011), triggering a cascade that results in increased
levels of many cytokines that have been shown to be increased
in the lungs and the circulation of patients with PAH (Dromparis
et al., 2010).562 Cell Metabolism 19, April 1, 2014 ª2014 Elsevier Inc.These data support the hypothesis that mitochondria may be
critical for the pathogenesis of PAH and the basis of a potential
comprehensive PAH theory (Dromparis et al., 2010; McMurtry
et al., 2004; Michelakis et al., 2002b; Sutendra et al., 2010,
2011b). This theory is emerging in parallel to an intriguing theory
that describes a previously unrecognized causal role of mito-
chondrial remodeling to the progression of cancer (Vander Hei-
den, 2011; Vander Heiden et al., 2009).
The Metabolic Theory of PAH
Lessons from Cancer
PAH shares many common features with cancer. Similar germ-
line mutations in the gene for BMPRII have been described in
PAH and cancer (Howe et al., 2001; Newman et al., 2001)
and oncoproteins such as survivin (McMurtry et al., 2005)
or Pim1 (Paulin et al., 2011) are upregulated both in the remod-
eled PAH pulmonary arteries and cancer. HIF1a is activated in
both PAH and cancer, even in the absence of hypoxia, and
tyrosine kinase signaling is upregulated in both conditions
(Klein et al., 2008; Schermuly et al., 2005). One of the markers
of cancer mitochondria is that they are much more hyperpolar-
ized in comparison to mitochondria from healthy cells (Bonnet
et al., 2007a; Chen, 1988). Similarly, PASMCs from humans
or animals with PAH are more hyperpolarized than mitochon-
dria from normal PASMCs (Dromparis et al., 2013b; McMurtry
et al., 2004; Sutendra et al., 2010, 2011a, 2011b). Because
the mitochondrial transition pore (MTP; a megachannel asso-
ciated with the release of proapoptotic mediators such as
cytochrome c and AIF to the cytoplasm) is voltage-gated,
this hyperpolarization is associated with an increase in
the threshold of MTP opening contributing to resistance to
apoptosis (Dromparis and Michelakis, 2013; Zamzami and
Kroemer, 2001)
The metabolic theory of cancer stems from the provocative
suggestion of Warburg (1930) that suppression in mitochondrial
function is not a result of cancer but, rather, contributes to its
cause. We now know that suppression of the mitochondria-
based respiration and glucose oxidation offers several advan-
tages to rapidly proliferating cancer cells (Gatenby and Gillies,
2004; Vander Heiden et al., 2009). Suppressed mitochondrial
respiration and glucose oxidation leads to hyperpolarization
and inhibition of apoptosis as discussed above. In addition,
metabolites or lipids that are normally oxidized in mitochondria
can instead be used in amino acid synthesis or membrane build-
ing in proliferating cells (DeBerardinis et al., 2008; Vander Heiden
et al., 2009). Cancer cells can respond to the decrease in the
mitochondrial production of ATP by increasing glucose uptake
and upregulating the production of ATP with cytoplasmic glycol-
ysis. This gives cancer cells a distinct ‘‘glycolytic’’ metabolic
profile and explains the fact that glucose uptake in tumors
(measured by positron emission tomography [PET] imaging) is
perhaps the most sensitive way to separate cancer from neigh-
boring healthy tissues. It also suggests that metabolism and
mitochondria can provide therapeutic targets specific to cancer
tissues, a direction that is now actively pursued (Vander Heiden,
2011; Vander Heiden et al., 2009). Therefore, if similar metabolic
changes are also present in PAH patients, then similar mitochon-
dria-targeting therapies may provide selectivity and efficacy in
PAH patients as well.
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Suppressed Glucose Oxidation and Its Effects on Cellular
Signaling in PAH. Recent studies showed that PAH PASMC
mitochondria have suppressed glucose oxidation and increased
cytoplasmic glycolysis (similarly to cancer, the upregulated
glycolysis is most likely a secondary effect in an attempt to
compensate and upregulate ATP synthesis in the cytoplasm)
and that, central to this, is an inhibition of the glucose oxidation
gatekeeping enzyme PDH (Sutendra et al., 2010, 2011a, 2011b;
Sutendra and Michelakis, 2013b). Inhibition of PDH decreases
the metabolism of pyruvate into the mitochondria (PDH cata-
lyzes the conversion of pyruvate into acetyl-CoA in the mito-
chondria), and, as a result, the function of the Krebs cycle and
ETC complexes is inhibited. The production of mROS (produced
in ETC complexes) and Krebs mediators such as aKG are also
decreased in PAH PASMCs (Sutendra et al., 2010, 2011a,
2011b). This has direct signaling implications. The suppression
in mROS production results in the inhibition of membrane Kv
channels (the ones inhibited in HPV leading to pulmonary vaso-
constriction), which, in turn, causes an increase in intracellular
calcium (Weir et al., 2005). This primary decrease in mROS as
well as the decrease in aKG, which has been shown to be an
important cofactor for the HIF1a destabilizing prolyl-hydroxy-
lases (MacKenzie et al., 2007), can contribute to the activation
of HIF1a (Sutendra et al., 2013a), a well-described observation
in PAH arteries, even in the absence of hypoxia (Bonnet et al.,
2006; Tuder et al., 2001). The increase in calcium as well as
the inhibition of the metabolic enzyme glycogen synthase kinase
3b, a consequence of the suppressed glucose oxidation (Pastor-
ino et al., 2005; Sutendra et al., 2010), both lead to the activation
of NFAT in PAH PASMCs, which directly promotes proliferation
(Bonnet et al., 2007b; Macian, 2005). Both HIF1a and NFAT
are master transcription factors, and their activation has been
well-described in cancer and PAH pathology (Bonnet et al.,
2006, 2007b) (Figure 3). Interestingly, they both lead to a down-
regulation of Kv channel expression (which has been a well-
documented observation in many human and animal PAH
models [Michelakis and Weir, 2001; Yuan et al., 1998]) as well
as downregulation of many mitochondrial factors and metabolic
enzymes, contributing to the suppression of glucose oxidation
(Bonnet et al., 2006, 2007b). For example, HIF1a leads to the
activation of PDH kinase (PDK), which inhibits PDH (Kim et al.,
2006; Semenza, 2012). In other words, the activation of these
transcription factors initiates a feedforward feedback loop that
sustains the PAH cellular phenotype even in vitro.
The importance of the PDH inhibition in PAH is supported by
the fact that the activation of PDH with molecular or pharmaco-
logic interventions both prevents and reverses established PAH
in several animal models. For example, the activation of PDH by
small molecules (such as the PDK inhibitor dichloroacetate),
drugs such as trimetazidine (a malonyl-CoA decarboxylase
[MCD]-like inhibitor that, by suppressing fatty acid oxidation
[FAO] promotes glucose oxidation via the Randle cycle), or
molecular (small interfering RNA [siRNA]-induced inhibition of
PDK) and genetic interventions (knockdown of MCD in mice)
prevent and reverse established PAH in vivo and normalize the
cellular PAH PASMC phenotype, including many downstream
abnormalities (downregulation of Kv channels, activation of
HIF1a and NFAT, increased intracellular calcium levels, prolifer-ative diathesis, and apoptosis resistance) (Figures 3 and 4)
(McMurtry et al., 2004; Michelakis et al., 2002b; Sutendra
et al., 2010, 2011a, 2011b). Interestingly, dichloroacetate also
showed promise in decreasing tumor growth in a variety of
animal cancer models (Bonnet et al., 2007a; Sutendra et al.,
2013a) as well as in a small mechanistic clinical trial in patients
with glioblastoma (Michelakis et al., 2010), suggesting that
similar metabolic-altering drugs tried in cancer may also be
beneficial in clinical PAH.
This discussion explains how the inhibition of PDH can cause
PAH with many of its previously described molecular features.
But what is the cause of the inhibition of PDH and glucose oxida-
tion in PAH? There are many potential causes that can be group-
ed into extra- and intramitochondrial causes.
Extramitochondrial Causes of PDH andGlucose Oxidation Inhibi-
tion in PAH. Activation of HIF1a or tyrosine kinases, both of
which have been described in animal and human PAH (Bonnet
et al., 2006; Ghofrani et al., 2005), can upregulate and activate
PDK, respectively, and thus inhibit PDH (Hitosugi et al., 2011;
Kim et al., 2006). Another way that PDH can be inhibited in
PAH is via a suppression of its function. For example, PDH (as
well as many other critical mitochondrial enzymes [Rizzuto
et al., 2004; Szabadkai and Duchen, 2008]) is very calcium-
dependent. Therefore, a decrease in mitochondrial Ca2+ could
cause PDH inhibition. Recent evidence suggests that ER stress,
a recognized feature of the remodeled PAH vessels since 1979
(Smith and Heath, 1979), may in fact cause a decrease in mito-
chondrial calcium. Here is how.
Mitochondrial suppression can be caused by a functional
disruption of the ER-mitochondria unit, given that the ER pro-
vides the mitochondria with the calcium required for the activa-
tion of many mitochondrial enzymes. The shape of the ER is
critical for maintaining this functional unit, and the reticulon pro-
tein Nogo has been shown to regulate ER shape (de Brito and
Scorrano, 2008; GrandPre´ et al., 2000; Voeltz et al., 2006).
Nogo expression is also induced during ER stress (Belmont
et al., 2008) in part because of the activation of the ATF6 axis,
an arm of the ER stress response that provides prosurvival
signals. The Nogo-induced increase in the ER-mitochondria
distance (disruption of the ER-mitochondria unit) decreases
mitochondrial calcium, causing mitochondrial suppression and
inhibition of mitochondria-mediated apoptosis. As a result,
PASMCs lacking Nogo do not develop the PAHphenotype under
hypoxia, and Nogo knockout mice are resistant to the develop-
ment of chronic-hypoxia-induced pulmonary hypertension (Su-
tendra et al., 2011b). ER stress is present in many conditions
associated with PAH, including mutations to BMPRII (which
can result in the accumulation of unfolded protein aggregates
[Sobolewski et al., 2008]), HIV and HSV infections (Cool et al.,
2003; Sehgal et al., 2009; Sitbon et al., 2008; Voelkel et al.,
2008), upregulation of Notch3 in PAH (Li et al., 2009), hypoxia,
or inflammation (Hotamisligil, 2010). Attenuation of ER stress
with small-molecule chemical chaperones such as phenylbuta-
rate (PBA) that limit the unfolded protein response reverse the
mitochondrial abnormalities and the cellular phenotype of PAH
(Dromparis et al., 2013a). Importantly, PBA (which, like dichlor-
oacetate, is a generic drug and has been used in humans for
other indications) both prevents and reverses established PAH
in two different rodent PAH models (Dromparis et al., 2013a).Cell Metabolism 19, April 1, 2014 ª2014 Elsevier Inc. 563
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Figure 4. Activation of PDH and Mitochondrial Signaling in PAH Animals Reverses the Disease
Representative pulmonary artery traces with a high-fidelity catheter advanced in the main pulmonary artery through the jugular vein show that PAH animals have
increased pulmonary artery pressures, which are normalized by dichloroacetate (DCA; top). Histology sections frommedium-sized pulmonary arteries show that
PAH animals have increased medial thickening, which is reversed by DCA (bottom).
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duction of cytokines such as IL-6 and CCL2/MCP1, which, in
turn, promote the activation and recruitment of macrophages
in the lung (Yeager et al., 2012). ER stress is a feature of PAH
PAEC as well. In fact, a structurally abnormal ER (suggesting
ER stress) was prominent in the early classic descriptions of
PAH pathology by Smith and Heath (1979).
There are many other examples in which well-characterized
pathways in PAH can also lead to mitochondrial suppression.
Examples include activation of STAT3 (Paulin et al., 2011) or
decreased BMPRII (Spiekerkoetter et al., 2013) and PPARg
signaling (Rabinovitch, 2010), all of which can converge and sup-
press mitochondrial function (Paulin et al., 2011; Rabinovitch,
2012). For example, STAT3 can activate NFAT, whereas BMPRII
axis inhibition, as discussed above, can cause ER stress (in the
case of mutated dysfunctional BMPRII receptors that disturb
cellular trafficking) or inhibit PPARg signaling (Hansmann et al.,
2008), which, in turn, inhibits mitochondrial biogenesis.
Mitochondrial Fission and Biogenesis. Mitochondrial suppres-
sion has recently been linked to increased activity of dynamin-
related protein 1 (DRP-1), a large GTPase involved in mito-
chondrial fission and the subsequent entry to the G2-M phaseFigure 3. Intriguing Similarities in the Mitochondrial Regulation of HIF1
Cancer cells and PAH pulmonary artery smooth muscle cells have increased mi
ester (TMRM) shown in red (nuclear stain with DAPI is shown in blue). Hypoxia-in
transcription factors activated in cancer and PAH vascular cells (merge with nu
chondrial signaling molecules, which include mitochondrial-derived reactive oxyg
expression of Kv1.5, which is decreased in both cancer and PAH pulmonary vascu
membrane potential, decreases nuclear localization of HIF1a and NFAT, and inc
reversal of both tumor growth and PAH in animals in vivo. This figure is modified wof cell-cycle progression in PAH PASMCs (Marsboom et al.,
2012a). These processes are coordinated by shared reliance
on the mitosis initiating kinase cyclin B1-CDK1. This kinase
phosphorylates DRP-1 at serine 616, leading to fission. This
mechanism ensures equitable distribution of mitochondria to
daughter cells during mitosis. Suppression of DRP-1 by siRNA
or the DRP-1 inhibitor Mdivi-1 prevented mitochondrial fission,
decreased proliferation, provoked apoptosis, and prevented
hypoxia-induced pulmonary hypertension (Marsboom et al.,
2012a). Similar mechanisms appear to occur in various cancers
(Rehman et al., 2012). Increased mitochondrial fission was
recently associated with decreased activation of peroxisome
proliferator-activated receptor gamma coactivator 1a (PGC1a),
a transcription factor that positively regulates mitochondrial
biogenesis (Ryan et al., 2013). PGC1a is a transcriptional coac-
tivator of PPARg, and there is a reciprocal relationship between
the expressions of these two important mitochondrial mediators
that is disordered in PAH (Hansmann and Zamanian, 2009).
Therefore, in PAH PASMCs, an increase in mitochondrial fission,
a decrease in mitochondrial fusion, and a decrease in mitochon-
drial biogenesis appear to contribute to the overall mitochondrial
suppression observed in PAH.a, NFAT, and Kv1.5 in Cancer and PAH
tochondrial membrane potential measured with tetramethylrhodamine methyl
ducible factor 1a (HIF1a) and nuclear factor of activated T cells (NFAT) are two
clear stain DAPI; blue) when mitochondrial function is suppressed and mito-
en species and a-ketoglutarate, are decreased. HIF1a and NFAT regulate the
lar cells. Activation of pyruvate dehydrogenase (PDH) decreasesmitochondrial
reases the protein levels of Kv1.5. These in vitro effects were associated with
ith permission fromBonnet et al. (2007a) and Sutendra et al. (2010) and (2013a).
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activation, BMPRII inhibition, STAT3 activation, and PGC1a
inhibition or ER-stress-causing conditions, including viral infec-
tions, BMPRII mutations, inflammation, or hypoxia) can cause
a secondary inhibition of PDH or mitochondrial function in
general (Figure 5). Obviously, many of the involved factors (for
example, HIF1a, NFAT, STAT3, PPARg, etc.), in addition to the
fact that they contribute to a suppression of mitochondrial
function, also have their primary effects, directly promoting
proliferation and contributing to the pathogenesis of PAH via
nonmitochondrial pathways.
Intramitochondrial Causes of PDH and Glucose Oxidation Inhibi-
tion. Primary (i.e., polymorphisms or mutations) abnormalities
in PDH are possible but have not been studied. Recent work
has shown that the mitochondrial protein uncoupling protein 2
(Ucp2; a mitochondria-specific calcium transporter and not an
uncoupling protein, as its name implies) is directly involved in
PAH pathogenesis. Ucp2 deficiency results in a decrease in
mitochondrial calcium levels and thus inhibition of the many
mitochondrial enzymes (including PDH) that are heavily cal-
cium-dependent as well as mitochondrial hyperpolarization (as
the levels of the positively charged calcium ions decrease in
the mitochondria) (Dromparis et al., 2013b). Ucp2-deficient
mice develop spontaneous pulmonary hypertension and show
activation of both NFAT and HIF1a and decreasedmitochondrial
glucose oxidation in PASMCs (Dromparis et al., 2013b). This
work directly links primary mitochondrial dysfunction to PAH
pathogenesis in mice. In humans, there are loss-of-function
SNPs that have been described in the Ucp2 gene that are asso-
ciated with the metabolic syndrome (Jia et al., 2009), similar to
what is observed in PAH patients. Given that polymorphisms in
Ucp2 are relatively common, and, given the fact that PAH re-
mains relatively rare, these SNPs could predispose individuals
toward PAH as part of a multiple-hit mechanism. The complexity
of PAH overall and its similarities with cancer make such a mul-
tiple-hit hypothesis quite likely.
Another intriguing but less-studied observation is that pa-
tients with PAH show evidence of anemia and dysfunctional
iron homeostasis (Rhodes et al., 2011a, 2011b). Iron is a critical
substrate for mitochondria as Fe-S clusters (exclusively formed
in mitochondria) are essential components of ETC complexes
and enzymes such as succinate dehydrogenase or aconitase
(Rouault and Tong, 2005). A general mitochondrial dysfunction,
which includes iron overloaded mitochondria, characterizes
the increasing list of human diseases that are caused by
mutations that disrupt Fe-S clusters and iron homeostasis
in mitochondria (Rouault and Tong, 2008). The emerging
clinical evidence suggests that PAH may belong to this list of
diseases.
Recent evidence suggests that the SOD2 gene, which en-
codes for the mitochondrial protein manganese superoxide dis-
mutase (MnSOD), is hypermethylated, resulting in decreased
expression of MnSOD, contributing to the observed decrease
in mROS in PAH PASMCs (Archer et al., 2010a). Treatment
with the DNAmethyltransferase inhibitor 5-aza-20-deoxycytidine
restored MnSOD expression, decreased proliferation, and
increased apoptosis in PAH PASMCs (Archer et al., 2010a). In
PAH, it is interesting that this epigenetic regulation appears to
be specific to the pulmonary arteries, and this relates to tissue-566 Cell Metabolism 19, April 1, 2014 ª2014 Elsevier Inc.specific upregulation of DNA methyltransferases 1 and 3 in pul-
monary, but not systemic, arteries (Archer et al., 2010a).
Altogether, these data underlie the importance of the presence
of several positively reinforcing feedback loops in PAH (for
example, HIF1a activation causes mitochondrial inhibition, but
primary mitochondrial inhibition can also activate HIF1a)
(Figure 5). This may explain why the molecular phenotype in
PAH is so difficult to normalize and why these changes persist
in vascular PAH PA cell studies in vitro. It also shows how,
whether there is a nonmitochondrial signal or a mitochondria-
specific signal, eventually, mitochondrial function is suppressed
in PAH. In other words, mitochondrial suppression may either
directly cause PAH or facilitate its progression.
Most of the data discussed above are based on PASMC
studies. Similar metabolic alterations, such as increased glycol-
ysis (again, most likely secondary to a primary suppression of
mitochondrial glucose oxidation) are also found in proliferative
PAECs from animals and humans with PAH (Hagan et al.,
2011; Xu and Erzurum, 2011; Xu et al., 2007). Recent evidence
suggests that VEGF-B controls endothelial uptake and transport
of fatty acids, resulting in insulin resistance and type 2 diabetes
(Hagberg et al., 2012). Enhanced mitochondrial FAO can indi-
rectly suppress glucose oxidation by the Randle cycle. This sug-
gests that VEGF-B signaling could also be important in PAH
pathogenesis by increasing fatty acid uptake and potentially
FAO, resulting in suppressed glucose oxidation. Decreasing
VEGF-B signaling in rodent models of type 2 diabetes restores
insulin sensitivity and glucose tolerance (Hagberg et al., 2012).
It remains to be determined whether the inhibition of VEGF-B
signaling in proliferative PASMCs or PAECs could be beneficial
by enhancing glucose oxidation.
Although potential similar mitochondrial changes in the fibro-
blasts, which are involved in the PAH vascular pathology, have
not been studied yet, metabolic-modulating therapies that aim
to increase glucose oxidation and decrease glycolysis may be
effective against both proliferative PASMCs and PAECs in the
pulmonary artery wall of patients with advanced PAH.
Metabolic Changes in PAH Skeletal Muscle
PAH patients appear to have insulin resistance similar to patients
with type 2 diabetes (Zamanian et al., 2009), suggesting that
these patients may have an overall metabolic dysfunction. This
metabolic syndrome in PAH patients comes in the absence of
obesity or diabetes and appears to be associated with a worse
prognosis in comparison to PAH patients that do not have evi-
dence of insulin resistance (Zamanian et al., 2009). The expres-
sion of apolipoprotein E (apoE) and PPARg are decreased in PAH
tissues, and apoE-deficient mice fed a high-fat diet develop PAH
and insulin resistance (Hansmann et al., 2007). Treatment with
the PPARg agonist rosiglitazone improved insulin sensitivity
and reversed PAH in these animals (Hansmann et al., 2007).
Mice forced to a doxycyclin-driven universal expression of a
BMRII mutation described in a HPAH family (R899X mutation
in the BMPRII tail domain) develop pulmonary vascular remodel-
ing but also gain weight when fed the same calories and while
having the same activity level as wild-type animals (West et al.,
2013). These mice consume 10% less oxygen and have
increased fasting insulin levels and insulin resistance in compar-
ison to controls. An index of insulin resistance in muscle (i.e., the
accumulation of lipids; see Figure 1) was present in the BMPRII
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Perspectivemutant PAH mice and absent in the control mice. Importantly,
feeding the mutant mice with high-fat diet significantly increased
the disease penetrance in these mice, increasing RV systolic
pressure (while systemic hemodynamics remained unaltered).
Although the authors postulated defects in the trafficking of the
glucocorticoid receptor mediating the metabolic consequences
of the BMPRII mutations, the exact mechanism remains to be
elucidated. Considering that BMPRII mutations have been
shown to trigger the unfolded protein response in cells in vitro
(Sobolewski et al., 2008), it is possible that ER stress may be
an important factor in the biology of these mice, triggering mito-
chondrial suppression as discussed above. The importance of
the West et al. (2013) data is that they showed that the insulin
resistance in mice is associated with skeletal muscle pathology
and that this precedes and is not a result of pulmonary vascular
remodeling and a decrease in cardiac output.
The involvement of skeletal muscle in PAH pathology provides
a strong basis for the clinical signs of insulin resistance in PAH
patients. The accumulation of lipids in skeletal muscle is indeed
a characteristic feature of patients with insulin resistance. For
example, the insulin resistance present in the skeletal muscle
of young (otherwise healthy) offspring of patients with type 2 dia-
betes is associated with the dysregulation of intramyocellular
fatty acid metabolism, possibly because of an inherited defect
in mitochondrial oxidative phosphorylation (Petersen et al.,
2004) or decreased mitochondrial number (Morino et al., 2005).
Intriguingly, in the skeletal muscle of patients with type 2 dia-
betes, an imbalance between glycolytic and oxidative phosphor-
ylation enzymatic activities, has been described (Simoneau and
Kelley, 1997), similar to the metabolic switch described in PAH
PASMCs and cancer. Furthermore, ER stress signaling is now
known to interfere with insulin signaling and promote insulin
resistance as well (Flamment et al., 2012; Samuel and Shulman,
2012). Studies of biopsies of skeletal muscle of PAH patients at
various stages of disease severity will help confirm or reject the
attractive hypothesis that a mitochondrial abnormality similar to
the one present in PAH pulmonary arteries is also present in skel-
etal muscle.
Metabolic Changes in the Right Ventricle
The hypertrophied RV in PAH also appears to be characterized
by a shift toward decreased mitochondrial glucose oxidation
and a glycolytic phenotype (Piao et al., 2010). Increasing mito-
chondrial glucose oxidation by treatment with dichloroacetate
or trimetazidine improves RV function ex vivo in an isolatedwork-
ing heart model with no significant direct effects on the normal
RV (Fang et al., 2012; Nagendran et al., 2008; Piao et al.,
2010). The fact that this happens ex vivo points to direct effects
of these drugs on the RVmyocardium and suggests that benefits
from metabolic modulators on the RV may be in addition to the
secondary benefits that will come from the reversal of the pulmo-
nary vascular remodeling from these drugs that will decrease RV
afterload. This suggests that similar metabolic-altering therapies
that are beneficial in the remodeled pulmonary arteries may also
have beneficial effects on the hypertrophied maladaptive RV.
However, the natural history of themetabolic remodeling (sup-
pressed glucose oxidation and increased glycolysis) on the RV
and whether this is sustained throughout the progression of
the RV remodeling from compensatory hypertrophy to decom-
pensated RV function remain unknown, and more studies areneeded. This is obviously important for determining whether
this metabolic modulation is contributing to the RV compensa-
tion toward the increased afterload. Although the increase in
contractility that occurs ex vivo in response to metabolic modu-
lators appears to be beneficial, whether it affects other factors
that contribute to the transition from compensation or decom-
pensation (for example, effects on angiogenesis and the
induction of apoptosis after prolonged exposure to metabolic
modulators) remains unknown. For example, the glycolytic shift
(as shown by increased glucose uptake measured by PET) is
associated with the compensatory stage of RV hypertrophy
but is lost (decreased glucose uptake) upon entrance to the
decompensation phase of RV function (Sutendra et al., 2013b).
At that point, an increase in the mROS production in RV cardio-
myocytes is seen, which is associated with HIF1a inhibition
and suppressed RV angiogenesis with ischemia potentially con-
tributing to RV decompensation (Sutendra et al., 2013b).
The metabolic remodeling in the RV offers great opportunities
for PET imaging, forming the basis of a potential prognostic
metabolic biomarker (Bokhari et al., 2011). This is even more
important, given that the same technique (glucose uptake mea-
surement by PET) can be used to detect the same metabolic re-
modeling on the pulmonary vasculature (Marsboom et al.,
2012b; Xu et al., 2007; Zhao et al., 2013), offering an opportunity
to simultaneously follow the metabolic remodeling in two of the
most important tissues in PAH.
Metabolic Changes in Immune Cells
Intriguingly, many of the immune cell types that are known to be
involved in PAH become highly glycolytic upon activation, sug-
gesting that these cells may also be responsive to metabolic-
altering therapies (Lunt and Vander Heiden, 2011; Shi et al.,
2011). Specifically, the glycolytic phenotype in activated T cells
(as opposed to quiescent T cells), which is associated with a
suppression of mitochondrial function (identical to the Warburg
effect that is present in cancer cells and the pulmonary vascular
cells discussed here) offers several advantages that contribute
to the proliferation and activation of these cells in disease states,
as reviewed recently (Pearce et al., 2013). In addition, ER stress
has also been observed in the circulating immune cells of PAH
patients (Lenna et al., 2013), which was associated with an in-
crease in the production of cytokines. This suggests that a
similar metabolic remodeling to PA vascular cells may be pre-
sent in activated immune cells of PAH patients. On the other
hand, many of the cytokines produced from these immune cells
that are known to be upregulated in PAH can also have direct
effects on the mitochondrial function of pulmonary vascular
cells. For example, TNFa can inhibit PDH activity in PASMCs,
resulting in the activation of NFAT and HIF1a, apoptosis resis-
tance, and enhanced proliferation (Sutendra et al., 2011a).
Inhibition of TNFa with etanercept normalized the metabolic
phenotype of PAH in vitro and reversed established PAH in vivo
(Sutendra et al., 2011a).
Very recent evidence, yet unexplored in PAH, suggests that
mitochondria can induce the inflammasome, initiating a cascade
of events that increases the levels of many inflammatory cyto-
kines described in PAH (Kepp et al., 2011). Given that PAH
PASMCs can also directly increase the production of cytokines
in an ER-stress-mediated fashion (Yeager et al., 2012), this sup-
ports the notion that the metabolic theory and inflammatoryCell Metabolism 19, April 1, 2014 ª2014 Elsevier Inc. 567
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many of the fundamental features of PAH.
Metabolic Changes in Endothelial Progenitor Cells
Whether these cells undergo a similar metabolic remodeling
similar to the immune cells or PAH vascular cells is unknown.
Certainly, endothelial cells from PAH pulmonary arteries do
have definitive evidence of increased glycolysis (Fijalkowska
et al., 2010; Xu et al., 2007). Although intriguing hypotheses
have suggested that these cells were recruited, it is not known
whether bone-marrow-derived endothelial progenitor cells
(EPCs; as opposed to resident EPCs in the PAs), have both a
proliferative and metabolic phenotype while in the bone marrow
of these patients (as opposed to adopting this phenotype after
they are recruited into the pulmonary vessels) (Tuder et al.,
1994; Yeager et al., 2011). Certainly, there is evidence that, in
diabetes and metabolic syndrome, there are dysfunctional
progenitor endothelial cells and that their dysfunction may be
partly due to abnormal mitochondrial proteins, such as sup-
pressed MnSOD expression and function (Devaraj and Jialal,
2012; Marrotte et al., 2010).
Therapeutic Implications of the Metabolic Theory
of PAH
Several agents that hold promise in the preclinical treatment
of PAHwere discussed above: PDK inhibitors such as dichloroa-
cetate (DCA), MCD inhibitors such as trimetazidine, PPARg
activators such as pioglitazone or rosiglitazone, NFAT inhibitors
such as cyclosporine, TNFa antagonists such as etanercept,
ER stress inhibitors such as phenylbutyrate, mitochondrial
fission inhibitors such as Mdivi-1, and MnSOD activators such
as MnTBAP or the DNA methyltransferase inhibitor 5-aza-20-
deoxycytidine, which increases MnSOD expression. They are
summarized in Figure 5. It is important to note that some of
these (such as DCA) have been tested in several PAH models
and human tissues and were able to improve hemodynamics,
RV function, vascular remodeling, and, importantly, the func-
tional capacity of the treated animals (exercise tolerance) and
their survival. In other words, in some cases, the preclinical
evidence is quite strong.
However, although most of these drugs have been tested in
humanswith other diseases (e.g., dichloroacetate, trimetazidine,
4-phenylbutyrate, etanercept, cyclosporine, pioglitazone, and
iron) they have yet to be tried in patients with PAH. A major chal-
lenge in the translation of this work in humans is that most of
these drugs are now generic (Sutendra and Michelakis, 2013a).
Nevertheless, a trial assessing the effects of DCA treatmentFigure 5. A Comprehensive Metabolic Theory in PAH Leads to the Dis
Suppressedmitochondrial PDH activity and glucose oxidation (GO) is central in PA
(DJm), inhibition of the mitochondrial permeability transition pore (MTP), and c
inducing factor to the mitochondria, leading to apoptosis resistance as well as
(mROS), a-ketoglutarate (aKG), or citrate, which overall contribute to the activati
hypoxia-inducible factor 1a (HIF1a) or epigenetic mechanisms, all of which pro
mitochondria-based inflammasomes. Mitochondrial GO suppression can result fr
pathogenesis (shown in yellow boxes) or intramitochondrial factors (shown in gree
UCP2 inhibition or Fe-S cluster disruption) may directly cause PAH, secondary m
tyrosine kinase [TK] signaling or BMPRII receptor signaling abnormalities) could a
Note that some of these factors (for example, the activation of NFAT or HIF1a) c
reinforcing feedback loops may explain the difficulty in reversing the PAH cellula
Marked in red are potential therapeutic targets with the relevant therapies shown
other diseases, facilitating their translation in humans. Experimental therapies min patients with advanced PAH is currently ongoing at the
University of Alberta and the Imperial College of Medicine (clin-
ical trial NCT01083524). Ongoing trials from Stanford University
are studying the effects of PPARg activators and NFAT inhibitors
in PAH patients (clinical trials NCT00825266 and NCT01647945,
respectively). Finally, Imperial College and Cleveland Clinic
scientists are testing the efficacy of parenteral or oral iron
supplementation in patients with PAH (NCT01447628 and
NCT01446848).
A Global Metabolic Dysfunction in PAH?
What is the underlying mechanism that may explain the global
metabolic remodeling in several organs in PAH patients? One
possibility is germline polymorphisms in mitochondrial proteins.
As discussed earlier, the ER stress in many tissues that may be
associated with germline mutations such as BMPRII, a global
disturbance in iron homeostasis and Fe-S cluster assembly, or
the mitochondrial effects of inflammation, may also be involved.
An additional exciting, but yet unexplored, possibility is that
diffusible mitochondrial products may have paracrine and sys-
temic effects, particularly given that some of these have been
found to be present in the blood of animals and patients. There
may be a circulating factor(s) that causesmitochondrial suppres-
sion globally, but the results of this suppression may be more
apparent in certain organs in which glucose oxidation or the
mitochondrial signaling in response to oxidative stress is more
critical than in others. There are two exciting possibilities that
are worth exploring in future research.
Mitokines and Humanin
Recently, mitochondria from one organ have been shown to
secrete yet unidentified circulating factors and ‘‘condition’’
remote organs (Durieux et al., 2011; Woo and Shadel, 2011).
This exciting work suggests that, when mitochondria from one
organ become dysfunctional, they can signal mitochondria
from other tissues by releasing diffusible factors known as mito-
kines (Durieux et al., 2011; Woo and Shadel, 2011). In addition,
humanin, which is transcribed from an open reading framewithin
the mitochondrial 16S rRNA, can also be secreted (Guo et al.,
2003) and is implicated in insulin resistance and vascular disease
(Muzumdar et al., 2009).
Circulating Succinate, a-ketoglutarate, and G-Protein-
Coupled Receptors
These Krebs cycle products are diffusible small molecules that
are also measurable in the blood, suggesting that they may exert
systemic effects. Although not tested in PAH, it was recently
shown that they can bind to orphanG-protein-coupled receptorscovery of Promising PAH Therapies
H pathogenesis and results in (1) increasedmitochondrial membrane potential
onfinement of proapoptotic mediators such as cytochrome c and apoptosis-
(2) decreased generation of mitochondria-derived reactive oxygen species
on of transcription factors such as nuclear factor of activated T cells (NFAT) or
mote cellular proliferation, and (3) promotion of inflammation via activation of
om either extramitochondrial abnormalities that are known to contribute to PAH
n boxes). In other words, although primarymitochondrial abnormalities (such as
itochondrial involvement due to extramitochondrial triggers (such as enhanced
lso contribute to the pathogenesis or facilitate the progression of the disease.
an be both a cause and a result of mitochondrial suppression. Such positively
r phenotype, which persists in vitro even when the primary trigger is removed.
in the box. Most of these therapies have already been tested in humans with
arked by an asterisk are currently undergoing clinical trials in PAH patients.
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Perspectivein vascular cells and regulate the angiotensin axis in systemic
vascular disease models (He et al., 2004).
Concluding Remarks
In summary, the metabolic theory of PAH can explain many
facets of the disease phenotype in response to diverse and
seemingly unrelated triggers and provides therapeutic targets
leading to the normalization of the cellular phenotype and mean-
ingful reversal of the disease in vivo. Metabolic modulation may
have the advantage of also reversing the multiple extrapulmo-
nary abnormalities in PAH that, in addition to the PA vessels,
include the RV, the immune system, or even the skeletal muscle.
Themetabolic theory also provides potential imaging biomarkers
because metabolism can be assessed with several well-devel-
oped imaging approaches, including PET.
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